Taysha Gene Therapies, Inc.
NASDAQ: TSHA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sean Nolan
- Employees
- 73
- Headquarters
- Dallas, United States
- IPO year
- 2020
- Market cap
- $1.7B
- Website
- https://www.tayshagtx.com
Loading TSHA…
Loading profile data…Frequently asked questions about TSHA
What does Taysha Gene Therapies, Inc. (TSHA) do?
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at...
Where does TSHA trade?
Taysha Gene Therapies, Inc. (TSHA) trades on the NASDAQ Global Select.
What sector is TSHA in?
Taysha Gene Therapies, Inc. (TSHA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Taysha Gene Therapies, Inc.?
Sean Nolan is the chief executive officer of Taysha Gene Therapies, Inc. (TSHA).
Where is Taysha Gene Therapies, Inc. headquartered?
Taysha Gene Therapies, Inc. is headquartered in United States.
Does TSHA pay a dividend?
Taysha Gene Therapies, Inc. (TSHA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TSHA go public?
Taysha Gene Therapies, Inc. (TSHA) completed its initial public offering in 2020.